Sanofi reported an excellent Q3, with all divisions supporting the strong top-line momentum. Moreover, better sales and tight control over operations aided profitability improvements and, hence, underpinned another full-year outlook upgrade. While Sanofi has been (very) late in its COVID-19 vaccine ambitions, the strong potential in most other areas remains intact and supports our positive stock recommendation.